J&J faces CDC ad­vi­so­ry com­mit­tee again next week to weigh Covid-19 vac­cine risks

The CDC’s Ad­vi­so­ry Com­mit­tee on Im­mu­niza­tion Prac­tices punt­ed ear­li­er this week on de­cid­ing whether or not to rec­om­mend lift­ing a pause on the ad­min­is­tra­tion of J&J’s Covid-19 vac­cine, but the com­mit­tee will meet again in an emer­gency ses­sion next Fri­day to dis­cuss the safe­ty is­sues fur­ther.

The tim­ing of the meet­ing like­ly means that the J&J vac­cine will not re­turn to the US mar­ket be­fore the end of next week as the FDA looks to work hand-in-hand with the CDC to en­sure the ben­e­fits of the vac­cine still out­weigh the risks for all age groups.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.